Jubilee Enterprises of Thailand: Growing through insights

Family offices are no longer quiet custodians of wealth. Based on the IMD-FBN Global Family Office Report - one of the most comprehensive family-first studies of its kind - they are evolving into multidimensional platforms that anchor both financi...

Transformational leadership is recognized for bringing family members together; however, its role in multi-unit complex family firms that rely on nonfamily managers is poorly theorized. We find that transformational family chief executive officers...

There is another entrepreneurial world that is born not from opportunity but from necessity, and it has much to teach us.

As in any conflict resolution, tackling problems in family firms begins by identifying where the problem originates and its precise nature.

For the team at Oculis, the announcement of the new USD 100 million fundraising could not have come at a more opportune moment. The biopharmaceutical startup was founded in 2017 to transform ophthalmology by developing not only original delivery mechanisms but also groundbreaking treatments for eye diseases like Diabetic Macular Edema (DME). Established by seasoned industry experts, Oculis aimed to replace invasive eye treatments with more accessible, patient-friendly solutions such as topical eye drops. The initial research conducted in a laboratory in Iceland led to a pipeline of drug candidates, now at various stages of clinical testing. The firm continued to ramp up thanks to successive rounds of financing from top investors and partners, totaling more than USD 500 million at the end of 2024. However, it also faced some dramatic events, including the sudden death in early 2024 of its CTO. The company continued to scale, strategically balancing clinical advancements with regulatory milestones. The recent secondary offering on Nasdaq would accelerate the clinical development pipeline, in particular its novel neuroprotective candidate Prisosegtor (OCS-05), OCS-01, a topical eye drop for DME, and OCS-02, a topical biologic eye drop candidate for dry eye disease. Oculis now grappled with a number of strategic decisions, with two questions in particular concerning the team. Should it rely mostly on outsourcing production to a contract development and manufacturing organization (CDMO) or develop its own in-house manufacturing capabilities? There were strong benefits and drawbacks to both approaches. It faced a related dilemma with its product pipeline. Should it continue to rely on its own R&D, as in the past, or should it consider acquiring technologies outside, through M&A activities?

Melisa Sabanci Tapan shares how redefining values and embracing AI helps preserve family legacy while staying human in a digital world

Though often invoked as a source of continuity, identity, and strategy, legacy remains conceptually underdeveloped and practically elusive. Leaders frequently grapple with how to preserve what matters from the past while enabling renewal, especial...

Exclusive IMD data reveals how the future of family offices is shifting as they invest in human and social capital while redefining identity to stay competitive.

While often perceived as locally embedded and less inclined toward international expansion, many family businesses rank among the world’s most successful companies, combining global growth with the preservation of family identity, values, and cont...

Family offices are experiencing a profound transformation. Once quiet back-office structures, they have become strategic engines at the heart of family wealth, legacy, and innovation. This report, a collaboration between IMD and FBN, explores how ...